Compare MTEN & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEN | ACXP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 6.8M |
| IPO Year | 2024 | 2021 |
| Metric | MTEN | ACXP |
|---|---|---|
| Price | $0.66 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | ★ 976.9K | 77.3K |
| Earning Date | 10-01-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,735,337.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.63 | N/A |
| 52 Week Low | $0.52 | $3.17 |
| 52 Week High | $26.03 | $25.00 |
| Indicator | MTEN | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 23.78 | 40.44 |
| Support Level | $0.52 | $3.98 |
| Resistance Level | $0.98 | $3.63 |
| Average True Range (ATR) | 0.19 | 0.31 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 21.81 | 18.86 |
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides an extensive product lineup including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in the automobile, construction machinery, and other manufacturing industries.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.